Amubarvimab

DB16493InvestigationalProtein Based Therapies

Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

Mechanism: BRII-196 is a human monoclonal antibody that is extracted from a recovered patient of COVID-19. Through binding to a highly conserved epitope on the Spike protein, BRII-196 displays blockage of viral entry and neutralization of live SARS-CoV-2 infection in cell culture assays. It is currently being investigated against COVID-19.
Curator reviewed
Also known as: IMMUNOGLOBULIN G1-KAPPA, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBODY
Code names: BRII-196

Resolves to

Compound

UNII2AD5KH3SE4CAS2509447-07-6

Targets

P0DTC2S

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amubarvimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account